Home » Asia Pacific

Thought Leadership

The Asia Pacific Center of Excellence has a deep knowledge of the nuanced differences within each market of the region, and understand when it is beneficial or necessary to gather insights from stakeholders beyond payers and physicians to answer our client’s questions.

Showing 5 of 11 posts
Oncology Market Access Opportunities 2020 NRDL
August 26, 2021 | Blogs

What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL

Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.

Cover Image for NRDL Market Access Rare Disease Therapies China 2020 NRDL
August 19, 2021 | Blogs

What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL

The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.

China NRDL 2020 Standout Features
January 27, 2021 | Infographics

China’s 2020 NRDL – Standout Features from the Finalized List

There have been several notable standout features in the 2020 NRDL including an update which saw manufacturer applications allowed for the first time compared to prior updates.

ISPOR Asia-Pacific 2020 Research Poster from CBPartners
September 7, 2020 | Research posters

ISPOR Asia-Pacific 2020: Comparison of Healthcare Systems and Opportunities for Innovative Drugs Across India, Vietnam, and Indonesia

A research poster that aims to understand how various healthcare system archetypes in APAC markets (e.g., India, Vietnam, and Indonesia) lead to access for high-cost innovative oncology treatments.

ISPOR Asia-Pacific 2020 Research Poster
September 7, 2020 | Research posters

ISPOR Asia-Pacific 2020: Dancing with the Dragon – Considerations and Learnings in the 2019 China NRDL Negotiations

A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.